If you would like to request a PDF for any of the below Research in Addiction Medicine Scholars (RAMS) published papers, please contact Jules Canfield, Program Manager, at email@example.com
Brothers TD, Walley AY, Rivers-Bowerman H, McLeod M, Genge L. Grayken lessons: between a rock and a hard place? A 37-year-old man with acute liver injury while enrolled in a managed alcohol program for severe alcohol use disorder. Addict Sci Clin Pract. 2023;18(1):14. PMCID: PMC9988200
Habersham LL. An unexpected path to addiction medicine. Am J Obstet Gynecol MFM. 2023;5(3):100849. PMCID: PMC9974569.
Harvey L, Kimmel SD, Edelman EJ. Meeting the moment: More infectious disease physicians must be prepared to provide buprenorphine. Clin Infect Dis. 2023;76(7):1205-1208. PMID: 36695340.
Kleinman RA, Sanches M. Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic. Drug Alcohol Depend. 2023;242:109703. PMCID: PMC9674402.
Lewer D, Brothers TD, Harris M, Rock KL, Copeland CS. Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: A thematic framework analysis of coroner reports. PLoS One. 2023;18(4):e0283549. PMCID: PMC10115296.
Peterkin AF, Jawa R, Menezes K, You J, Cabral H, Ruiz-Mercado G, Park TW, Kehoe J, Taylor JL, Weinstein ZM. Pre-paid phone distribution: A tool for improving healthcare engagement for people with substance use disorder. Subst Use Misuse. 2023;58(4):585-589. PMID: 36695079.
Thakrar AP, Uritsky TJ, Christopher C, Winston A, Ronning K, Sigueza AL, Caputo A, McFadden R, Olenik JM, Perrone J, Delgado MK, Lowenstein M, Compton P. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder. Addict Sci Clin Pract. 2023;418(1):13. PMCID: PMC9951406.
Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin PO, Jain V. Comparative 1-year outcomes of invasive Staphylococcus aureus infections among persons with and without drug use: An observational cohort study. Clin Infect Dis. 2022;74(2):263-270. PMCID: PMC8800187.
Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin P, Jain V. Patient-directed discharges among persons who use drugs hospitalized with invasive Staphylococcus aureus infections: Opportunities for improvement. Am J Med. 2022;135(1):91-96. PMID: 34508704
Bahji A, Bach P, Danilewitz M, Crockford D, El-Guebaly N, Devoe DJ, Saitz R. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction. 2022;117(10):2591-2601. PMCID: PMC9969997.
Bahji A, Bach P, Danilewitz M, Crockford D, Devoe DJ, El-Guebaly N, Saitz R. Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis. J Addict Med. 2022;16(6):630-638. PMCID: PMC10010623.
Bahji A, Brothers TD, Danilewitz M. Considering Cannabis Use in Differential Diagnosis: A Teachable Moment. JAMA Intern Med. 2022;182(1):66-67. PMCID: PMC8881091.
Bahji A, Crockford D, El-Guebaly N. Management of post-acute alcohol withdrawal: A mixed-studies scoping review. J Stud Alcohol Drugs. 2022;83(4):470-479. PMCID: PMC9798381.
Bahji A, Milloy MJ, Bach P, Sociás ME. Challenges and opportunities for further research involving the cannabis-to-opioid use transition. Addiction. 2022;117(10):2752-2754. PMCID: PMC9949991.
Bahji A, Zarate CA, Vazquez GH. Efficacy and safety of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(6):853-866. PMCID: PMC9949988.
Brothers TD, Fraser J, MacAdam E, Morgan B, Webster D. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder. Drug Alcohol Rev. 2022;41(2):430-434. PMCID: PMC8814044.
Brothers TD, Leaman M, Bonn M, Lewer D, Atkinson J, Fraser J, Gillis A, Gniewek M, Hawker L, Hayman H, Jorna P, Martell D, O’Donnell T, Rivers-Bowerman H, Genge L. Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug Alcohol Depend. 2022;235:109440. PMCID: PMC8988445.
Brothers TD, Lewer D, Jones N, Colledge-Frisby S, Farrell M, Hickman M, Webster D, Hayward A, Degenhardt L. Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: A cohort study in New South Wales, Australia. PLoS Med. 2022;19(7):e1004049. PMCID: PMC9295981.
Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. PLoS One. 2022;17(1):e0263156. PMCID: PMC8791472.
Ferguson M, Medley A, Rittenbach K, Brothers TD, Strike C, Ng J, Leece P, Elton-Marshall T, Ali F, Lorenzetti DL, Buxton JA. Priority setting for Canadian take-home naloxone best practice guideline development: an adapted online Delphi method. Harm Reduct J. 2022;19(1):71. PMCID: PMC9250272.
Harris MTH, Laks J, Stahl N, Bagley SM, Saia K, Wechsberg WM. Gender dynamics in substance use and treatment: A women’s focused approach. Med Clin North Am. 2022;106(1):219-234. PMCID: PMC8881090.
Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Behavioral risk factors for HIV infection in hospitalized persons who co-use stimulants and opioids. AIDS Behav. 2022;26(4):1047-1055. PMCID: PMC8435119.
Jawa R, Murray S, Tori M, Bratberg J, Walley A. Federal policymakers should urgently and greatly expand naloxone access. Am J Public Health. 2022;112(4):558-561. PMCID: PMC8961838.
Jawa R, Walley AY, Wilson DJ, Green TC, McKenzie M, Hoskinson R Jr, Bratberg J, Ramsey S, Rich JD, Friedmann PD. Prescribe to save lives: Improving buprenorphine prescribing among HIV clinicians. J Acquir Immune Defic Syndr. 2022;90(5):546-552. PMCID: PMC9283214.
Jawa R, Laks J, Saravanan N, Demers L, Wishik-Miller G. Physician trainees’ compassion satisfaction, burnout, and self-efficacy when caring for people who inject drugs. Subst Abus. 2022;43(1):675-681. PMID: 34666627
Jawa R, Rozansky H, Clemens D, Fagan M, Walley AY. Rethinking home-based outpatient parenteral antibiotic therapy for persons who inject drugs: An opportunity for change in the time of COVID-19. J Addict Med. 2022;16(2):e70-e72. PMCID: PMC8501142.
Klaire S, Janssen RM, Olson K, Bridgeman J, Korol EE, Chu T, Ghafari C, Sabeti S, Buxton JA, Lysyshyn M. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada. Int J Drug Policy. 2022;106:103741. PMCID: PMC9970175
Kleinman RA, Weiss RD. Benzodiazepine-involved overdose deaths in the USA: 2000-2019. J Gen Intern Med. 2022;37(8):2103-2109. PMCID: PMC9198172.
Kleinman RA, Sanches M. Impacts of eliminating audio-only care on disparities in telehealth accessibility. J Gen Intern Med. 2022;37(15):4021-4023. PMCID: PMC8999992.
Kleinman RA, Brothers TD, Danilewitz M, Bahji A. Office-based methadone prescribing for opioid use disorder: the Canadian model. J Addict Med. 2022;16(5):499-504. PMCID: PMC9271524.
Kimmel SD, Rosenmoss S, Bearnot B, Weinstein Z, Yan S, Walley AY, Larochelle MR. Northeast postacute medical facilities disproportionately reject referrals for patients with opioid use disorder. Health Aff (Millwood). 2022;41(3):434-444. PMID: 35254930
Levander XA, Pytell JD, Stoller KB, Korthuis PT, Chander G. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Subst Abus. 2022;43(1):633-639. PMCID: PMC8810732.
Levander XA, Wheelock H, Pope J, Lee A, Hartmann K, Abuelkhair S, Gregg JL, Buchheit BM. Low-threshold buprenorphine via community partnerships and telemedicine- Case reports of expanding access to addiction treatment during COVID-19. J Addict Med. 2022;16(1):e56-e58. PMCID: PMC8815644.
Morford KL, Tetrault JM, Zhou B, Li F, Gleeson B, Edelman EJ, Stein MD, Barry DT, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug Alcohol Depend. 2022;241:109707. PMCID: PMC9777057.
Nolan S, Kelian S, Kerr T, Young S, Malmgren I, Ghafari C, Harrison S, Wood E, Lysyshyn M, Holliday E. Harm reduction in the hospital: An overdose prevention site (OPS) at a Canadian hospital. Drug Alcohol Depend. 2022;239:109608. PMCID: PMC9970047.
Pytell JD, Thakrar AP, Chander G, Colantuoni E. Changes in alcohol consumption by beverage type attributable to the COVID-19 pandemic for 10 states, March 2020 to November 2020: An ecological simulation-based analysis. J Addict Med. 2022;16(6):e412-e416. PMCID: PMC9653060.
Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. Drug Alcohol Rev. 2022;41(2):444-448. PMCID: PMC8926080.
Thakrar AP. Short-acting opioids for hospitalized patients with opioid use disorder. JAMA Intern Med. 2022;182(3):247-248. PMID: 35099508
Thakrar AP, Kleinman RA. Opioid withdrawal management in the fentanyl era. Addiction. 2022;117(9):2560-2561. PMID: 35373864.
Touesnard N, Brothers TD, Bonn M, Edelman EJ. Overdose deaths and HIV infections among people who use drugs: shared determinants and integrated responses. Expert Rev Anti Infect Ther. 2022;20(8):1061-1065. PMID: 35615917.
Wang A, Jawa R, Mackin S, Whynott L, Buchholz C, Childs E, Bazzi AR. “We were building the plane as we were flying it, and we somehow made it to the other end”: syringe service program staff experiences and well-being during the COVID-19 pandemic. Harm Reduct J. 2022;19(1):78. PMCID: PMC9284956.
Zolopa C, Brothers TD, Leclerc P, Mary JF, Morissette C, Bruneau J, Hyshka E, Martin NK, Larney S. Changes in supervised consumption site use and emergency interventions in Montréal, Canada in the first twelve months of the COVID-19 pandemic: An interrupted time series study. Int J Drug Policy. 2022;110:103894. PMCID: PMC9574459.
Brothers TD, Fraser J, Webster D. Caring for people who inject drugs when they are admitted to hospital. CMAJ. 2021;193(12):E423-E424. PMCID: PMC8096383
Brothers TD, Kaulbach J, Tran A. Unhealthy alcohol use in a 65-year-old man awaiting surgery. CMAJ. 2021;193(32):E1250-E1252. PMCID: PMC8386484.
Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review. BMJ Open. 2021;11(8):e049924. PMCID: PMC8354281.
Brothers TD, Lewer D, Thakrar AP. Linking opioid use disorder treatment from hospital to community. Addiction. 2021;116(8):2244-2245. PMCID: PMC8511949
De Aquino JP, Flores JM, Avila-Quintero VJ, Compton P, Sofuoglu M. Pharmacological treatment of pain among persons with opioid addiction: A systematic review and meta-analysis with implications for drug development. Addict Biol. 2021;26(4):e12964. PMID: 3297499
De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425-436. PMCID: PMC8020374
Harris MTH, Bagley SM, Maschke A, Schoenberger SF, Sampath S, Walley AY, Gunn CM. Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose.” J Subst Abuse Treat. 2021;125:108313. PMCID: PMC8140193
Harris MTH, Peterkin A, Bach P, Englander H, Lapidus E, Rolley T, Weimer MB, Weinstein ZM. Adapting inpatient addiction medicine consult services during the COVID-19 pandemic. Addict Sci Clin Pract. 2021;16(1):13. PMCID: PMC7903401
Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, Turnbull J. Outcomes of Ottawa, Canada’s Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int J Drug Policy. 2021;98:103400. PMCID: PMC8881087.
Jawa R, Saravanan N, Burrowes SAB, Demers L. A call for training graduate medical students on harm reduction for people who inject drugs. Subst Abus. 2021;42(3):266-268. PMID: 34086530
Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. Int J Drug Policy. 2021;94:103198. PMCID: PMC8373634
Kimmel SD, Rosenmoss S, Bearnot B, Larochelle M, Walley AY. Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts. J Addict Med. 2021;15(1), 20–26. PMCID: PMC7859880
Labonté LE, Young S. High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers. Harm Reduct J. 2021;18(1):87. PMCID: PMC8361239.
Levander XA, Vega TA, Seaman A, Korthuis T, Englander H. Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis. Subst Abus. 2022;43(1):245-252. PMCID: PMC8695635
Levander XA, Vega TA, Seaman A, Korthuis PT, Englander H. Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs. Int J Drug Policy. 2021;96:103356. PMCID: PMC8568624.
Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, Farrell M, Petersen I. Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study. PLoS Med. 2021;18(10):e1003759. PMCID: PMC8491890.
Pytell JD, Sklar MD, Carrese J, Rastegar DA, Gunn C, Chander G. “I’m a survivor”: Perceptions of chronic disease and survivorship among individuals in long-term remission from opioid use disorder. J Gen Intern Med. 2021;37(3):593-600. PMCID: PMC8141362
Roy PJ, Price R, Choi S, Weinstein ZM, Bernstein E, Cunningham CO, Walley AY. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021;224:108703. PMCID: PMC8180499
Tang VM, Le Foll B, Blumberger DM, Voineskos D. Repetitive Transcranial Magnetic Stimulation for Comorbid Major Depressive Disorder and Alcohol Use Disorder. Brain Sci. 2021;12(1):48. PMCID: PMC8773947.
Vega TA, Levander XA, Seaman A, Korthuis T, Englander H. “Sobriety equals getting rid of hepatitis C”: A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. J Subst Abuse Treat. 2021;37(3):593-600.PMCID: PMC8217723
Young S, Hayashi K, Grant C, Milloy MJ, DeBeck K, Wood E, Fairbairn N. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada. Drug Alcohol Depend. 2021 Nov 1;228:109006. PMCID: PMC8812726.
Appa A, Rowe C, Hessol NA, Coffin P. Beyond overdose: Drug-related deaths in people with and without HIV in San Francisco, 2007-2018. Open Forum Infect Dis. 2020;7(12), ofaa565. PMCID: PMC7757430
Bach P, Hayashi K, Milloy MJ, Nosova E, Kerr T, Wood E, Fairbairn N. Characterising the increasing prevalence of crystal methamphetamine use in Vancouver, Canada, from 2006-2017: A gender-based analysis. Drug Alcohol Rev. 2020;39(7):932-940. PMCID: PMC7683370
Calcaterra SL, Binswanger IA, Edelman EJ, McNair BK, Wakeman SE, O’Connor PG. The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: A survey of hospitalist physicians. Subst Abus. 2020;1–9. PMCID: PMC7541600
Harris M, Joseph K, Hoeppner B, Wachman EM, Gray JR, Saia K, Wakeman S, Blair-Merritt MH, Schiff DM. A retrospective cohort study examining the utility of perinatal urine toxicology testing to guide breastfeeding initiation. J Addict Med. 2021;15(4):311-317. PMCID: PMC8044259
Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug Alcohol Depend. 2020;211:107968. PMCID: PMC7529685
Kim JH, Fine DR, Li L, Kimmel SD, Ngo LH, Suzuki J, Price CN, Ronan MV, Herzig SJ. Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study. PLoS Med. 2020;17(8), e1003247. PMCID: PMC7413412
Kimmel S, Bach P, Walley AY. Comparison of treatment options for refractory opioid use disorder in the United States and Canada: a narrative review. J Gen Intern Med. 2020;35(8):2418-2426. PMCID: PMC7403280
Kimmel SD, Miller NS. The clinical microbiology laboratory and the opioid epidemic: Challenges and opportunities. Infect Dis Clin of North Am. 2020;34(3), 465–478. PMCID: PMC7428057
Kimmel SD, Walley AY, Linas BP, Kalesan B, Awtry E, Dobrilovic N, White L, LaRochelle M. Effect of publicly reported aortic valve surgery outcomes on valve surgery in injection drug- and non-injection drug-associated endocarditis. Clin Infect Dis. 2020;71(3):480-487. PMCID: PMC7384313
Komaromy M, Harris M, Koenig RM, Tomanovich M, Ruiz-Mercado G, Barocas JA. “Caring for COVID’s most vulnerable victims: A safety-net hospital responds.” Res Sq. 2020;rs.3.rs-97328. PMCID: PMC7605557
Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what? Subst Abus. 2020;41(1):110-120. PMID: 31403914
Roy PJ, Choi S, Bernstein E, Walley AY. Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. J Subst Abuse Treat. 2020;114, 108011. PMID: 32527508
Bach P, Hartung D. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addict Sci Clin Pract. 2019;14(1):30. PMCID: PMC6717996
Bozinoff N, Luo L, Dong H, Krüsi A, DeBeck K. Street-involved youth engaged in sex work at increased risk of syringe sharing. AIDS Care. 2019; 31(1):69-76. PMCID: PMC6250570
Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone matters: What the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019; 10.1007/s11606-018-4801-3. PMCID: PMC6544670
Dean A, Kimmel S. Free trade and opioid overdose death in the United States. SSM Popul Health. 2019;8:100409. PMCID: PMC6606896
Manhapra A, Chakraborty A, Arias AJ. Topiramate pharmacotherapy for alcohol use disorder and other addictions: A narrative review. J Addict Med. 2019;13(1):7-22. PMID: 30096077
Pytell JD, Buresh ME, Graddy R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract. 2019;14(1):46. PMCID: PMC6921403
Vaezazizi LM, Campbell ANC, Pavlicova M, Hu MC, Nunes EV. Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders. J Subst Abuse Treat. 2019;105:64-70. PMCID: PMC8459398
Bagley SM, Cheng DM, Winter M, Alford DP, LaBelle C, Walley AY, Samet JH. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests. Drug Alcohol Depend. 2018; 192:245-249. PMCID: PMC6291245
Bone CW, Goodfellow AM, Vahidi M, Gelberg L. Prevalence of sexual violence and its association with depression among male and female patients with risky drug use in urban federally qualified health centers. J Urban Health. 2018; 95(1): 111-115. PMCID: PMC5862699
Bozinoff N, Anderson BJ, Bailey GL, Stein MD. Correlates of stigma severity among persons seeking opioid detoxification. J Addict Med. 2018; 12(1):19-23. PMCID: PMC5786480
Chang DC, Klimas J, Wood E, Fairbairn N. A case of opioid overdose and subsequent death after medically supervised withdrawal: The problematic role of rapid tapers for opioid use disorder. 2018; 12(1):80-83. PMCID: PMC5786466
Jun JH, Fairbairn N. Integrating injectable opioid agonist treatment into a drug treatment court program: A case study. Subst Abus. 2018; 39(4): 493-496. PMCID: PMC6750900
Klimas J, Dong H, Fairbairn N, Socías E, Barrios R, Wood E, Kerr T, Montaner J, Milloy MJ. Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting. Addict Sci Clin Pract. 2018; 13(1):3. PMCID: PMC5812056
Lundsberg LS, Peglow S, Qasba N, Yonkers KA, Gariepy AM. Is preconception substance use associated with unplanned or poorly timed pregnancy?. J Addict Med. 2018; 12(4): 321-328. PMCID: PMC6066412
Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768-776. PMID: 29656707
Manhapra A, Arias AJ, Ballantyne JC. The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentary. Subst Abus. 2018;39(2):152-161. PMCID: PMC6129223
Peglow SL, Binswanger IA. Preventing opioid overdose in the clinic and hospital: Analgesia and opioid antagonists. Med Clin North Am. 2018; 102(4):621-634. PMCID: PMC6029888
Weinstein ZM, Gryczynski G, Cheng DM, Quinn E, Hui D, Kim HW, Labelle C, Samet JH. Tapering off and returning to buprenorphine maintenance in a primary care office based addiction treatment (OBAT) program. Drug Alcohol Depend. 2018; 189:166-171. PMCID: PMC6139651
Bozinoff N, Small W, Long C, DeBeck K, Fast D. Still “at risk”: An examination of how street-involved young people understand, experience, and engage with “harm reduction” in Vancouver’s inner city. Int J Drug Policy. 2017; 45:33-39. PMCID: PMC5576444
Bozinoff N, Wood E, Dong H, Richardson L, Kerr T, DeBeck K. Syringe sharing among a prospective cohort of street-involved youth: Implications for needle distribution programs. AIDS Behav. 2017; 21(9):2717-2725. PMCID: PMC5640474
Fairbairn N, Wood E, Dobrer S, Dong H, Kerr T, Debeck K. The relationship between hazardous alcohol use and violence among street-involved youth. Am J Addict. 2017; 26(8):852-858. PMCID: PMC5730057
Fairbairn NS, Walley AY, Cheng DM, Quinn E, Bridden C, Chaisson C, Blokhina E, Lioznov D, Krupitsky E, Raj A, Samet JH. Mortality in HIV-infected alcohol and drug users in St.Petersburg, Russia. PLoS One. 2017; 11(11):e0166539. PMCID: PMC5127495
Hui D, Weinstein ZM, Cheng DM, Quinn E, Kim H, Labelle C, Samet JH. Very early disengagement and subsequent re-engagement in primary care office based opioid treatment (OBOT) with buprenorphine. J Subst Abuse Treat. 2017; 79:12-19. PMCID: PMC5522736
Lévesque A, Campbell AN, Pavlicova M, Hu MC, Walker R, McClure EA, Ghitza UE, Bailey G, Stitzer M, Nunes EV. Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav. 2017; 65:74-80. PMCID: PMC5483182
Lin LA, Bohnert ASB, Jannausch M, Goesling J, Ilgen MA. Use of non-pharmacological strategies for pain relief in addiction treatment patients with chronic pain. Am J Addict. 2017; 26(6):564-567. PMCID: PMC5576866
Manhapra A, Rosenheck R. Tobacco use disorder among patients with smoking-related chronic medical disease: Association with comorbid substance use disorders. J Addict Med. 2017; 11(4):293-299. PMCID: PMC 5537028
Nolan S, Walley AY, Heeren TC, Patts GJ, Ventura AS, Sullivan MM, Samet JH, Saitz R. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017; 29(9):1129-1136. PMCID: PMC5543330
Weinstein ZM, Cheng DM, Quinn E, Hui D, Kim H, Gryczynski G, Samet JH. Psychoactive medications and disengagement from office based opioid treatment (OBOT) with buprenorphine. Drug Alcohol Depend. 2017; 170:9-16. PMCID: PMC5183557
Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni ML, Bachman SS, Samet JH. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017; 74:65-70. PMCID: PMC5312773
Lévesque A, Roy É, Jutras-Aswad D, Zang G, Artenie AA, Bruneau J. Examining the link between psychological distress, mental health disorders and sharing behaviors among cocaine users. Addict Behav. 2016; 62:54-9. PMID: 28103534
Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016; 160:82-9. PMCID: PMC4767635
Mortazavi BJ, Downing NS, Bucholz EM, Dharmarajan K, Mahapra A, Li SX, Negahban SN, Krumholz HM. Analysis of machine learning techniques for heart failure readmissions. Circ Cardiovasc Qual Outcomes. 2016; 9(6):629-640. PMCID: PMC5459389
Stein MD, Kanabar M, Anderson BJ, Lembke A, Bailey GL. Reasons for benzodiazepine use among persons seeking opioid detoxification. J Subst Abuse Treat. 2016; 68:57-61. PMCID: PMC4955948
Wilder CM, Miller SC, Tiffany E, Winhusen T, Winstanley EL, Stein MD. Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. J Addict Dis. 2016; 35(1):42-51. PMCID: PMC4751580
Bagley SM, Peterson J, Cheng DM, Jose C, Quinn E, O’Connor PG, Walley AY. Overdose education and naloxone rescue kits for family members of individuals who use opioids: Characteristics, motivations, and naloxone use. Subst Abus. 2015; 36(2):149-54. PMCID: PMC4809347
Manhapra A, Stefanovics E, Rosenheck R. Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinence. Drug Alcohol Depend. 2015; 156:70-77. PMCID: PMC4633308
Park TW, Cheng DM, Samet JH, Winter MR, Saitz R. Chronic care management for substance dependence in primary care among patients with co-occurring disorders. Psychiatr Serv. 2015; 66(1):72-9. PMCID: PMC4282827
Tofighi B, Grossman E, Buirkle E, McNeely J, Gourevitch M, Lee JD. Mobile phone use patterns and preferences in safety net office-based buprenorphine patients. J Addict Med. 2015; 9(3):217-21. PMCID: PMC4693598
Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract. 2014; 9(1):19. PMCID: PMC4166410
Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, Wood E. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014; 109(12):2053-9. PMCID: PMC4229435
Park TW, Bohnert AS, Austin KL, Saitz R, Pizer SD. Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy. Psychiatr Serv. 2014; 65(1):4. PMCID: PMC5697151